维普期刊资源整合服务平台（V6.5）

54篇 您的检索式：作者名="BLESSING P"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Bone morphongenetie protein -4 is required for mesoderm formation and patterning in the mouse显示文摘	WINNIER G BLESSING M LABOSKY P A	1995	Genes Dev1995，9，：	1
2	Bone Mor- phogenetic protein-4 (BMP-4) is required for meso- derm formation and patterning in the mouse 显示文摘	Winnier G Blessing M Labosky P A	1995	Genes Dev1995，，9：	1
3	Bone morphogenetic protein-4is required for mesoderm formation and patterning in the mouse显示文摘	WINNIER G BLESSING M LABOSKY P A	1995	Genes Dev1995，9，：	1
4	Bone morphogenetic protein 4 is required for mesoderm formation and patterning in the mouse显示文摘	Winner G Blessing M Labosky P A	1995	Genes Dev1995，9，：	1
5	Phase Ⅱ evaluation of liposomal doxorubicin ( Doxil ) in recurrent or advanced leiomyosarcoma of the uterus:a Gynecologic Oncology Group Study 显示文摘	Sutton G Blessing J Hanjani P	2005	Gynecol Oncol2005，96，3：	1
6	Overexpression of bone morphogenetic protein-6(BMP-6)in the epidermis of transgenic mice:inhibition or stimulation of proliferation depending on the pattern of transgene expression and formation of psoriatic lession显示文摘	Blessing M Schirmacher P Kaiser S		0，，：	1
7	Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse显示文摘	Winnier G Blessing M Labosky P A	1995	Genes Dev1995，9，17：	1
8	Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group study 显示文摘	McGuire W P Blessing J A Bookman M A	2000	J Clin Oncol2000，18，5：	1
9	Phase Ⅱ evaluation of liposomal doxorubicin(Doxil) in recurrent or advanced leiomyosarcoma of the uterus:a Gynecologic Oncology Group study显示文摘	Sutton G Blessing J Hanjani P	2005	Gynecol Oncol2005，96，3：	1
10	Topotecan in squamous cell carcinoma of the cervix: A Phase Ⅱ study of the Gynecologic Oncology Group 显示文摘	Bookman MA Blessing JA Hanjani P	2000	Gynecol Oncol2000，77，3：	1
11	Phase Ⅲ study of cisplatin with or without paclitaxel in stage IVB,recurrent,or persistent squamous cell carcinoma of the cervix:a gynecologic oncology group study显示文摘	Moore D H Blessing J A McQuellon R P	2004	J Clin Oncol2004，22，15：	1
12	Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix:a Gynecologic Oncology Group Study显示文摘	Bonomi P Blessing JA Stehman FB	1985	J Clin Oncd1985，3，：	1
13	Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study显示文摘	Rose P G Blessing J A Mayer A R	1998	J Clin Oncoi1998，16，2：	1
14	Passive autofocus for digital endoscopic imaging systems显示文摘	BLESSING P ORELLI A V NIEDERER P		0，，：	1
15	Randomized trialof three cisplatin dose schedules in squamous-cell carcinoma ofthe cervix:a Gynecologic Oncology Group study显示文摘	Bonomi P Blessing JA Stehman FB	1985	J ClinOncol1985，3，8：	1
16	Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study 显示文摘	DAVID H MOORE J A BLESSING R P	2004	J Clin Oncol2004，22，15：	1
17	Biosynthesis of lysine in plants: evidence for a variant of the known bacterial pathways显示文摘	Hudson A O Bless C Macedo P	2005	Biochim Biophys Acta2005，1721，13：	1
18	Phase Ⅱ evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus:a Gynecologic Oncology Group study显示文摘	Sutton G Blessing J Hanjani P	2005	Gynecol Oncol2005，96，3：	1
19	Interaction of selenium compounds with zinc finger proteins involved in DNA repair 显示文摘	Blessing H Kraus S Heindl P	2004	Bal Europ Biochem2004，271，15：	1
20	Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a gynecologic oncology group study 显示文摘	Curtin J P Blessing J A Webster K D	2001	J Clin Oncol2001，19，5：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示